[
1. Adeolu, M., Gupta, R. S., 2014: A phylogenomic and molecular marker based proposal for the division of the genus Borrelia into two genera: the emended genus Borrelia containing only the members of the relapsing fever Borrelia, and the genus Borreliella gen. nov. containing the members of the Lyme disease Borrelia (Borrelia burgdorferi sensu lato complex). Antonie Van Leeuwenhoek, 105, 6, 1049—1072. DOI: 10.1007/s10482-014-0164-x.10.1007/s10482-014-0164-x24744012
]Search in Google Scholar
[
2. Aronowitz, R. A., 2012: The rise and fall of the lyme disease vaccines: a cautionary tale for risk interventions in American medicine and public health. Milbank Q, 90, 2, 250—277. DOI: 10.1111/j.1468-0009.2012.00663.x.10.1111/j.1468-0009.2012.00663.x346020822709388
]Search in Google Scholar
[
3. Bencurova, E., Gupta, S. K., Oskoueian, E., Bhide, M., Dandekar, T., 2018: Omics and bioinformatics applied to vaccine development against Borrelia. Mol. Omics., 14, 5, 330—340. DOI: 10.1039/c8mo00130h.10.1039/C8MO00130H
]Search in Google Scholar
[
4. Bensaci, M., Bhattacharya, D., Clark, R., Linden, T. Hu., 2012: Oral vaccination with vaccinia virus expressing the tick antigen subolesin inhibits tick feeding and transmission of Borrelia burgdorferi vaccination. Vaccine, 30, 42, 6040—6046. DOI: 10.1016/j.vaccine.2012.07.053.10.1016/j.vaccine.2012.07.053393895422864146
]Search in Google Scholar
[
5. Bins, A. D., Jorritsma, A., Wolkers, M. C., Hung, Ch. Fu., Wu, T. C., Schumacher, T. N. M., Haanen, J. B. A. G., 2005: A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat. Med., 11, 8, 899—904. DOI: 10.1038/nm1264.10.1038/nm126415965482
]Search in Google Scholar
[
6. Bunikis, J., Tsao, J., Luke, C. J., Luna, A. G., Fish, D., Barbour, A. G., 2004: Borrelia burgdorferi infection in a natural population of Peromyscus leucopus mice: a longitudinal study in an area where Lyme Borreliosis is highly endemic. J. Infect. Dis., 189, 8, 1515—1523. DOI: 10.1086/382594.10.1086/38259415073690
]Search in Google Scholar
[
7. CDC 24/7: Saving Lives, Protecting PeopleTM: Notice to Readers Availability of Lyme Disease Vaccine. https://www.cdc.gov/mmwr/preview/mmwrhtml/00056299.htm. Updated January 22, 1999. Accesed February 19, 2021.
]Search in Google Scholar
[
8. Comstedt, P., Hanner, M., Schüler. W., Meinke, A., Schlegl, R., Lundberg, U., 2015: Characterization and optimization of a novel vaccine for protection against Lyme borreliosis. Vaccine, 33, 44, 5982—5988. DOI: 10.1016/j. vaccine.2015.07.095.10.1016/j.vaccine.2015.07.095
]Search in Google Scholar
[
9. Earnhart, C. G., Buckles, E. L., Marconi, R. T, 2006: Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains. Vaccine, 25, 3, 466—480. DOI: 10.1016/j.vaccine.2006.07.052.10.1016/j.vaccine.2006.07.05216996663
]Search in Google Scholar
[
10. Earnhart, C. G., Marconi, R. T., 2007: Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens. Vaccine, 25, 17, 3419—3427. DOI: 10.1016/j. vaccine.2006.12.051.10.1016/j.vaccine.2006.12.051
]Search in Google Scholar
[
11. Embers, M. E., Narasimhan, S., 2013: Vaccination against Lyme disease: past, present, and future. Front. Cell Infect. Microbiol., 3, 6. DOI: 10.3389/fcimb.2013.00006.10.3389/fcimb.2013.00006356983823407755
]Search in Google Scholar
[
12. Federizon, J., Frye, A., Huang, W-C., Hart, T. M., He, X., Beltran, C., et al., 2020: Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes. Vaccine, 38, 4, 942—950. DOI: 10.1016/j.vaccine.2019.10.073.10.1016/j.vaccine.2019.10.073698077231727504
]Search in Google Scholar
[
13. Fingerle, V., Schulte-Spechtel, U. C., Ruzic-Sabljic, E., Leonhard, S., Hofmann, H., Weber, K., et al., 2008: Epidemiological aspects and molecular characterization of Borrelia burgdorferi s. l. from southern Germany with special respect to the new species Borrelia spielmanii sp. nov. Int. J. Med. Microbiol., 2, 279—290. DOI: 10.1016/j.ijmm.2007.05.002.10.1016/j.ijmm.2007.05.00217616434
]Search in Google Scholar
[
14. Gerritzen, M. J. H., Martens, D. E., Wijffels, R. H., Van der Pol, L., Stork, M., 2017: Bioengineering bacterial outer membrane vesicles as vaccine platform. Biotechnol. Adv., 35, 5, 565—574. DOI: 10.1016/j.biotechadv.2017.05.003.10.1016/j.biotechadv.2017.05.00328522212
]Search in Google Scholar
[
15. Gomes-Solecki, M., Arnaboldi, P. M., Backenson, P. B., Benach, J. L., Cooper, C. L., Dattwyler, R. J., et al., 2020: Protective immunity and new vaccines for Lyme disease. Clin. Infect. Dis., 70, 8, 1768—1773. DOI: 10.1093/cid/ciz872.10.1093/cid/ciz872715578231620776
]Search in Google Scholar
[
16. Gomes-Solecki, M. J. C., Brisson, D. R., Dattwyler, R. J., 2006: Oral vaccine that breaks the transmission cycle of the Lyme disease spirochete can be delivered via bait. Vaccine, 24, 20, 4440—4449: DOI: 10.1016/j.vaccine.2005.08.089.10.1016/j.vaccine.2005.08.08916198456
]Search in Google Scholar
[
17. Hassan, W. S., Giaretta, P. R., Rech, R., Ollivault- Shiflett, M., Esteve-Gasent, M., 2019: Enhanced protective efficacy of Borrelia burgdorferi BB0172 derived-peptide based vaccine to control Lyme disease. Vaccine, 37, 5596—5606. DOI: 10.1016/j.vaccine.2019.07.092.10.1016/j.vaccine.2019.07.09231387750
]Search in Google Scholar
[
18. Izac, J. R., O’Bier, N. S., Oliver, L. D., Camire, A. C., Earnhart, C. G., LeBlanc Rhodes, D. L. V., et al., 2020: Development and optimization of OspC chimeritope vaccinogens for Lyme disease. Vaccine, 38, 8,1915—1924. DOI: 10. 1016/j.vaccine.2020.01.027.10.1016/j.vaccine.2020.01.027708541031959423
]Search in Google Scholar
[
19. Jan, A. T, 2017: Outer membrane vesicles (OMVs) of Gram-negative bacteria: A perspective update. Front. Microbiol., 8, 1053. DOI: 10.3389/fmicb.2017.01053.10.3389/fmicb.2017.01053546529228649237
]Search in Google Scholar
[
20. Kamp, H. D., Swanson, K. A., Wei, R. R., Pradeep, K. D., Dharanipragada, R., Kern, A., Sharma, B., et al., 2020: Design of a broadly reactive Lyme disease vaccine. Npj. Vaccines, 5, 1, 1—10. DOI: 10.1038/s41541-020-0183-8.10.1038/s41541-020-0183-8719541232377398
]Search in Google Scholar
[
21. Khatchikian, C. E., Nadelman, R. B., Nowakowski, J., Schwartz, I., Wormser, G. P., Brisson, D., 2014: Evidence for strain-specific immunity in patients treated for early Lyme disease. Infect. Immun., 82, 4, 1408—1411. DOI: 10.1128/IAI. 01451-13.10.1128/IAI.01451-13
]Search in Google Scholar
[
22. Klouwens, M. J., Salverda, M. L. M., Trentelman, J. J., Ersoz, J. I., Wagemakers, A., Gerrizten, M. J., et al., 2021: Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis. Vaccine, 39,18, 2561—2567. DOI: 10.1016/j.vac cine.2021.03.059.10.1016/j.vaccine.2021.03.059
]Search in Google Scholar
[
23. Klouwens, M. J., Trentelman, J. J., Ersoz, J. I., Nieves Marques Porto, F., Sima, R., Hajdusek, O., et al., 2021: Investigating BB0405 as a novel Borrelia afzelii vaccination candidate in Lyme borreliosis. Sci. Rep., 11, 1, 4775. DOI: 10.1038/s41598-021-84130-y.10.1038/s41598-021-84130-y791057333637813
]Search in Google Scholar
[
24. Klouwens, M. J., Trentelman, J. J. A., Wagemakers, A., Ersoz, J. I., Bins, A. D., Hovius, J. W., 2021: Tick-tattoo: DNA vaccination against B. burgdorferi or Ixodes scapularis tick proteins. Front. Immunol., 12, 615011. DOI: 10.3389/fim mu.2021.615011.10.3389/fimmu.2021.615011
]Search in Google Scholar
[
25. Kuleš, J., Horvatić, A., Guillemin, N., Galan, A., Mrljak, V., Bhide, M., 2016: New approaches and omics tools for mining of vaccine candidates against vector-borne diseases. Mol. Biosyst., 12, 9, 2680—2694. DOI: 10.1039/C6MB00 268D.10.1039/C6MB00268D
]Search in Google Scholar
[
26. Kumar, M., Kaur, S., Kariu, T., Yang, X., Bossis, I., Anderson, J. F., et al., 2011: Borrelia burgdorferi BBA52 is a potential target for transmission blocking Lyme disease vaccine. Vaccine, 29, 48, 9012—9019, DOI: 10.1016/j.vaccine. 2011.09.035.10.1016/j.vaccine.2011.09.035
]Search in Google Scholar
[
27. Kung, F., Kaur, S., Smith, A. A.,Yang, X., Wilder, C. N., Sharma, K., et al., 2016: A Borrelia burgdorferi surface-exposed transmembrane protein lacking detectable immune responses supports pathogen persistence and constitutes a vaccine target. J. Infect. Dis., 213, 11, 1786—1795. DOI: 10.1093/infdis/jiw013.10.1093/infdis/jiw013485746826747708
]Search in Google Scholar
[
28. Kutzler, M. A., Weiner, D. B., 2008: DNA vaccines: ready for prime time ? Nat. Rev. Genet., 9, 10, 776—788. DOI: 10. 1038/nrg2432.10.1038/nrg2432431729418781156
]Search in Google Scholar
[
29. LaFleur, R. L., Callister, S. M., Dant, J. C., Jobe, D. A., Lovrich, S. D., Warner, T. F., et al., 2010: One-year duration of immunity induced by vaccination with a canine Lyme disease bacterin. Clin. Vaccine Immunol., 17, 5, 870—874. DOI: 10. 1128/CVI.00524-09.10.1128/CVI.00524-09286339720237200
]Search in Google Scholar
[
30. LaFleur, R. L., Dant, J. C., Wasmoen, T. L., Callister, S. M., Jobe, D. A., Lovrich, S., D., et al., 2009: Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. Clin. Vaccine Immunol., 16, 2, 253—259. DOI: 10. 1128/CVI.00373-08.10.1128/CVI.00373-08264353419052162
]Search in Google Scholar
[
31. Levy, S. A., 2002: Use of a C6 ELISA test to evaluate the efficacy of a whole-cell bacterin for the prevention of naturally transmitted canine Borrelia burgdorferi infection. Vet. Ther. Res. Appl. Vet. Med., 3, 4, 420—424.32.
]Search in Google Scholar
[
32. Levy, S. A., Millership, J., Glover, S., Parker, D., Hogan, J., Heldorfer, M., et al., 2010: Confirmation of presence of Borrelia burgdorferi outer surface protein C antigen and production of antibodies to Borrelia burgdorferi outer surface protein C in dogs vaccinated with a whole-cell Borrelia burgdorferi bacterin. Intern. J. Appl Vet. Med., 8, 3, 123—128.
]Search in Google Scholar
[
33. Little, S. E., Heise, S. R., Blagburn, B. L., Callister, S. M., Mead, P. S., 2010: Lyme borreliosis in dogs and humans in the USA. Trends Parasitol., 26, 4, 213–—218. DOI: 10.1016/j.pt.2010.01.006.10.1016/j.pt.2010.01.00620207198
]Search in Google Scholar
[
34. Mancini, F., Rossi, O., Necchi, F., Micholi, F., 2020: OMV vaccines and the role of TLR agonists in immune response. Int. J. Mol. Sci., 21, 12, 4416. DOI: 10.3390/ijms21124416.10.3390/ijms21124416735223032575921
]Search in Google Scholar
[
35. Marconi, R. T., Garcia-Tapia, D., Hoevers, J., Honsberger, N., King, V. L., Ritter, D., et al., 2020: VANGUARD®cr-Lyme: A next generation Lyme disease vaccine that prevents B. burgdorferi infection in dogs. Vaccine X, 6, 11, 100079. DOI: 10.1016/j.jvacx.2020.100079.10.1016/j.jvacx.2020.100079773314433336185
]Search in Google Scholar
[
36. Meirelles Richer, L., Aroso, M., Contente-Cuomo, T., Ivanova, L., Gomes-Solecki, M., 2011: Reservoir targeted vaccine for Lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice. Clin. Vaccine Immunol., CVI, 11, 18, 1809—1816. DOI: 10.1128/CVI.05226-11.10.1128/CVI.05226-11320901221918116
]Search in Google Scholar
[
37. Murfin, K. E., Fikrig, E., 2017: Tick bioactive molecules as novel therapeutics: Beyond vaccine targets. Front. Cell Infect. Microbiol., 7, 222. DOI: 10.3389/fcimb.2017.00222.10.3389/fcimb.2017.00222545989228634573
]Search in Google Scholar
[
38. Nadelman, R. B., Wormser G. P., 1998: Lyme borreliosis. Lancet, 352, 9127, 557—565. DOI: 10.1016/S0140-6736 (98)01146-5.10.1016/S0140-6736(98)01146-5
]Search in Google Scholar
[
39. Nardelli, D. T., Munson, E. L., Callister, S. M., Schell, R., 2009: Human Lyme disease vaccines: past and future concerns. Future Microbiol., 4, 4, 457—469. DOI: 10.2217/fmb. 09.17.10.2217/fmb.09.17
]Search in Google Scholar
[
40. Nayak, A., Schüler, W., Seidel, S., Gomez, I., Meinke, A., Comstedt, P., et al., 2020: Broadly protective multivalent OspA vaccine against Lyme borreliosis, developed based on surface shaping of the C-terminal fragment. Infect Immun., 88, 4. DOI: 10.1128/IAI.00917-19.10.1128/IAI.00917-19709314131932330
]Search in Google Scholar
[
41. Nelson, C. A., Saha, S., Kugeler, K. J., Delorey, M. J., Shankar, M. B., Hinckley, A. F., et al., 2015: Incidence of clinician-diagnosed Lyme disease, United States, 2005—2010. Emerg. Infect. Dis., 21, 9, 1625—1631. DOI: 10.3201/eid2109.150417.10.3201/eid2109.150417455014726291194
]Search in Google Scholar
[
42. Nigrovic, L. E., Thompson, K. M., 2007: The Lyme vaccine: a cautionary tale. Epidemiol. Infect., 135, 1, 1—8. DOI: 10. 1017/S0950268806007096.10.1017/S0950268806007096287055716893489
]Search in Google Scholar
[
43. Pereira, V. B., Zurita-Turk, M., Saraiva, T. D. L., De Castro, C. P., Souza, B. M., Agresti, P. M., et al., 2014: DNA vaccines approach: From concepts to applications. World J. Vaccines, 4, 2, 50—71. DOI: 10.4236/wjv.2014.42008.10.4236/wjv.2014.42008
]Search in Google Scholar
[
44. Plotkin, S. A., 2016: Need for a new Lyme disease vaccine. N. Engl. J. Med., 375, 10, 911—913. DOI: 10.1056/NEJMp 1607146.10.1056/NEJMp1607146
]Search in Google Scholar
[
45. Pol van der, L., Stork, M., Ley van der, P., 2015: Outer membrane vesicles as platform vaccine technology. Biotechnol. J., 10, 11, 1689—1706. DOI: 10.1002/biot.201400395.10.1002/biot.201400395476864626912077
]Search in Google Scholar
[
46. Poland, G. A., 2011: Vaccines against Lyme disease: What happened and what lessons can we learn ? Clin. Infect. Dis., 52, 253—258. DOI: 10.1093/cid/ciq116.10.1093/cid/ciq11621217172
]Search in Google Scholar
[
47. Radolf, J. D., Caimano, M. J., Stevenson, B., Hu, L. T., 2012: Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. Nat. Rev. Microbiol., 10, 2, 87—99. DOI: 10.1038/nrmicro2714.10.1038/nrmicro2714331346222230951
]Search in Google Scholar
[
48. Rizzoli, A., Hauffe, H. C., Carpi, G., Vourc’h, G. I., Neteler, M., Rosa, R., 2011: Lyme borreliosis in Europe. Eurosurveillance, 16, 27, 19906, 1—8. DOI: 10.2807/ese.16.27. 19906-en.10.2807/ese.16.27.19906-en
]Search in Google Scholar
[
49. RxList, 2016: Side Effects of Lymerix (Lipoprotein Outer Surface A Vaccine), Warnings, Uses. RxList. https://www.rx-list.com/lymerix-side-effects-drug-center.htm. Last reviewed on RxList April 29, 2016. Accessed February 19, 2021.
]Search in Google Scholar
[
50. Scheckelhoff, M. R., Telford, S. R., Hu, L. T., 2006: Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Vaccine, 24, 11, 1949—1957. DOI: 10.1016/j.vaccine. 2005.10.044.10.1016/j.vaccine.2005.10.044
]Search in Google Scholar
[
51. Schuijt, T. J., Hovius, J. W., Poll van der, T., Dam van, A. P., Fikrig, E., 2011: Lyme borreliosis vaccination: the facts, the challenge, the future. Trends Parasitol., 27, 1, 40—47. DOI: 10.1016/j.pt.2010.06.006.10.1016/j.pt.2010.06.00620594913
]Search in Google Scholar
[
52. Seinost, G., Golde, W. T., Berger, B. W., Dunn, J. J., Qiu, D., Dunkin, D. S., et al., 1999: Infection with multiple strains of Borrelia burgdorferi sensu stricto in patients with Lyme disease. Arch. Dermatol., 135, 11, 1329—1333. DOI: 10.1001/archderm.135.11.1329.10.1001/archderm.135.11.132910566830
]Search in Google Scholar
[
53. Sigal, L. H., Zahradnik, J. M., Lavin, P., Patella, S. J., Bryant, G., Haselby, R., et al., 1998: A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant outer-surface protein A Lyme disease. N. Engl. J. Med., 339, 4, 216—222. DOI: 10.1056/NEJM199807233390402.10.1056/NEJM1998072333904029673299
]Search in Google Scholar
[
54. Šmit, R., Postma, M. J., 2015: Lyme borreliosis: reviewing potential vaccines, clinical aspects and health economics. Expert. Rev. Vaccines, 14, 12, 1549—1561. DOI: 10.1586/1476 0584.2015.1091313.10.1586/14760584.2015.1091313
]Search in Google Scholar
[
55. Stanek, G., Wormser, G., Gray, J., Strle, F., 2012: Lyme borreliosis. Lancet, 379, 9814, 461—473. DOI: 10.1016/S01 40-6736(11)60103-7.10.1016/S0140-6736(11)60103-7
]Search in Google Scholar
[
56. Steere, A. C., Sikand, V. K., Meurice, F. Parenti, D. L., Fikrig, E., Schoen, R. T., et al., 1998: Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N. Engl. J. Med., 339, 4, 209—215. DOI: 10. 1056/NEJM199807233390401.10.1056/NEJM1998072333904019673298
]Search in Google Scholar
[
57. Steere, A. C., Strle. F., Wormser, G. P., Hu, L. T., Branda, J. A., Hovius, J. W. R., et al., 2016: Lyme borreliosis. Nat. Rev. Dis. Primer, 2, 16090. DOI: 10.1038/nrdp.2016.90.10.1038/nrdp.2016.90553953927976670
]Search in Google Scholar
[
58. Sykes, R. A., Makiello, P., 2017: An estimate of Lyme borreliosis incidence in western Europe. J. Public Health Oxf. Engl., 39, 1, 74—81. DOI: 10.1093/pubmed/fdw017.10.1093/pubmed/fdw01726966194
]Search in Google Scholar
[
59. Todaro, W. T., Schoen, R. T., 2000: The Lyme disease vaccine: Conception, development, and implementation. Ann. Intern. Med., 132, 8, 661—668.10.7326/0003-4819-132-8-200004180-0000910766685
]Search in Google Scholar
[
60. Töpfer, K. H., Straubinger, R. K., 2007: Characterization of the humoral immune response in dogs after vaccination against the Lyme borreliosis agent: A study with five commercial vaccines using two different vaccination schedules. Vaccine, 25, 2, 314—326. DOI: 10.1016/j.vaccine.2006.07.031.10.1016/j.vaccine.2006.07.03116930782
]Search in Google Scholar
[
61. Valneva, 2020: Valneva Announces Acceleration of Pediatric Development for Lyme Disease Vaccine Candidate—Valneva. https://valneva.com/press-release/valneva-announces-acceleration-of-pediatric-development-for-lyme-disease-vaccine-candidate/. Updated December 2, 2020. Accessed February 4, 2021
]Search in Google Scholar
[
62. Valneva, 2021: Valneva Announces Positive Initial Results for Phase 2 Study of Lyme Disease Vaccine Candidate—Valneva. https://valneva.com/press-release/valneva-announces-positive-initial-results-for-phase-2-study-of-lyme-disease-vaccine-candidate/. Updated July 22, 2020. Accessed February 4, 2021.
]Search in Google Scholar
[
63. Valneva, 2021: Valneva Announces Positive Initial Results for Second Phase 2 Study of Lyme Disease Vaccine Candidate VLA15—Valneva. https://valneva.com/press-release/valneva-announces-positive-initial-results-for-second-phase-2-study-of-lyme-disease-vaccine-candidate-vla15/. Updated October 20, 2020. Accessed February 4, 2021.
]Search in Google Scholar
[
64. Wagemakers, A., Mason, L. M. K., Oei, A., Wever de, B., Poll van der, T., Bins, A. D., et al., 2014: Rapid outer-surface protein C DNA tattoo vaccination protects against Borrelia afzelii infection. Gene Ther., 21, 1051—1057. DOI: 10. 1038/gt.2014.87.10.1038/gt.2014.8725273355
]Search in Google Scholar
[
65. We Respect Animals—Bioveta, 2015: Borrelym 3—new unique vaccine. https://www.bioveta.eu/en/news/news-in-assortment/borrelym-3-new-unique-vaccine.html: Updated March 3, 2015. Accesssed March 15, 2020.
]Search in Google Scholar